Taking ADCs targeting ERBB2 as an example, in theory, they should be effective against ERBB2 over-expressed/mutated cancers, including breast cancer, gastric cancer, urothelial carcinoma, colorectal cancer, and non-small cell lung cancer [23–27]. Here, ERBB2 is linked to breast cancer.